Jean M. Franchi, the Chief Financial Officer of Disc Medicine (IRON 1.66%), recently converted some stock into cash. Eleven thousand, one hundred and fifty-six shares, to be precise. About $720,000 worth. It happened on February 17th and 18th, 2026. A transaction recorded, of course, with the Securities and Exchange Commission. So it goes.
A Little Accounting
| Metric | Value |
|---|---|
| Shares sold (direct) | 11,156 |
| Transaction value | $720,000 |
| Post-transaction shares (direct) | 71,343 |
| Post-transaction value (direct ownership) | ~$4.6M |
The price used for valuation, according to the paperwork, was $64.51 per share. A number, really, like any other. It just happened to represent a tiny slice of ownership in a company trying to make people less sensitive to sunlight. A noble goal, I suppose.
Questions, Naturally
This sale was larger than anything Franchi had done before. A good bit larger. Previously, she’d moved 3,136 shares in February 2024. A mere rounding error in the grand scheme of things. It represented 13.52% of her direct holdings. A significant chunk. One wonders if she knew something the rest of us didn’t. Or perhaps she just needed the money. People do, you know.
The Company, Briefly
| Metric | Value |
|---|---|
| Market capitalization | $2.51B |
| Employees | 142 |
| Net Loss (TTM) | $212.18M |
| 1-year price change (as of Feb) | 22.33% |
Disc Medicine, you see, is a biotechnology company. They’re trying to fix blood diseases. Specifically, they’re focused on iron and how it gets around inside us. A complicated business.
What It Means, If Anything
The stock had been doing okay, actually. A few years of growth. But then the FDA rejected bitopertin, their drug for people who are allergic to the sun. A cruel irony, wouldn’t you say? The FDA had concerns about the data. And the potential for abuse. They always worry about abuse. So it goes.
Now, Disc is trying other ways to get the drug approved. But they also announced they were cutting 20% of their workforce. And their financial results weren’t great. A doubling of their net loss, year over year. Numbers, really. Just numbers. But numbers that tell a story. A story about risk. And about hope. And about the peculiar human habit of investing in things we don’t fully understand.
I’ve been looking at Disc Medicine for a while now. And I have to say, this feels like a turning point. A moment where the path forward becomes a lot less clear. A lot more… precarious. And that, my friends, is something to pay attention to. Even if you don’t quite understand why.
Read More
- Gold Rate Forecast
- Games That Faced Bans in Countries Over Political Themes
- Silver Rate Forecast
- Unveiling the Schwab U.S. Dividend Equity ETF: A Portent of Financial Growth
- 22 Films Where the White Protagonist Is Canonically the Sidekick to a Black Lead
- 20 Movies Where the Black Villain Was Secretly the Most Popular Character
- Superman Flops Financially: $350M Budget, Still No Profit (Scoop Confirmed)
- How to Do Sculptor Without a Future in KCD2 – Get 3 Sculptor’s Things
- Celebs Who Narrowly Escaped The 9/11 Attacks
- 14 Movies Where the Black Character Refuses to Save the White Protagonist
2026-03-01 22:13